Montelukast Teva (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Teva, is a leukotriene receptor antagonist presented as a tablet for oral use. It reduces bronchoconstriction and airway inflammation, treating asthma, exercise‑induced bronchoconstriction and allergic rhinitis in adults and children.

GNH USA supplies Montelukast Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist used to manage chronic airway and allergic conditions.

- Asthma: improves control of persistent asthma and reduces the frequency of exacerbations. - Exercise‑induced bronchoconstriction: prevents narrowing of airways triggered by physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes associated with seasonal allergies.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain in the head. - Abdominal pain: discomfort or cramps in the stomach area. - Nausea: feeling of queasiness, sometimes leading to vomiting. - Diarrhea: loose, watery stools. - Cough: persistent dry cough. - Sore throat: irritation or pain in the throat.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or anaphylaxis requiring immediate medical attention. - Neuropsychiatric events: mood changes, depression or suicidal thoughts. - Liver enzyme elevation: abnormal liver function tests. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Hematologic abnormalities: rare blood cell disorders. - Severe bronchospasm: paradoxical worsening of breathing.

Before prescribing Montelukast, clinicians should consider several safety aspects.

- Neuropsychiatric monitoring: watch for mood changes, depression or suicidal ideation. - Hepatic function: use with caution in patients with moderate to severe liver impairment. - Acute asthma: not indicated for immediate relief of acute bronchospasm. - Hypersensitivity: avoid in individuals with known allergy to Montelukast or any tablet excipients. - Pregnancy and lactation: safety data are limited; assess risk‑benefit ratio. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Phenobarbital: induces hepatic enzymes, reducing Montelukast plasma levels. - Rifampin: strong enzyme inducer that may lower therapeutic effect. - Ketoconazole: potent CYP3A4 inhibitor that can increase Montelukast exposure.

Moderate Interactions (Monitor Closely): - Beta‑agonists (e.g., albuterol): additive bronchodilator effect, monitor for excessive bronchodilation. - Aspirin and NSAIDs: may increase risk of bronchospasm in aspirin‑sensitive patients. - Other leukotriene modifiers (e.g., zafirlukast): combined use may increase adverse‑event risk.